For Research Use Only. Not for Clinical Use.

Creative Biolabs is a leading service provider that focuses on half-life extension for drug development. Based on our advanced platforms and extensive experience, now we can provide a series of half-life extension services against organ rejection for our clients all over the world.

Introduction of Half-life Extended Drug

Due to a series of advantages, such as specificity, high binding affinity, solubility as well as a low toxicity, therapeutic peptides and proteins present great potentials for diseases treatment. However, the relative molecular mass of these drug molecules is small, and they are easily cleared by the kidneys, resulting in a short half-life in the body. Therefore, it is necessary to maintain the drug effect through frequent administration during clinical use, which greatly limits the clinical application of such drugs. In this case, it is imminent to modify these drugs to prolong their efficacy.

Compared with traditional protein drugs, fusion protein drugs not only retain the biological activity of the original protein but also have an expanded molecular weight to extend the half-life of the drugs. Up to now, the indications of fusion protein drugs approved by the FDA cover autoimmune diseases, ophthalmological diseases, tumors, diabetes, etc.

Methods to Improve the Pharmacokinetic Behavior of Small Peptides and Proteins

• Increase the size and hydrodynamic radius of peptides and proteins.
• Increase the negative surface charge of peptides and proteins.
• Increase the serum protein level of proteins and peptides by connecting albumin and immunoglobulin.

Fig 1. High magnification micrograph of lung transplant rejection.

Application of Half-life Extended Drug in Organ Rejection

Organ rejection, also known as transplant rejection, is the process that occurs when a transplanted organ is rejected by the recipient's immune system. Depending on the timing after transplant, the type of organ rejection includes acute rejection and chronic rejection. Generally, after organ transplantation, the patient will need to take medication (immunosuppressive agent) for life to prevent the body from rejecting your new organ. A CTLA4-IgG1 Fc fusion protein, with a half-life of 8 days, has been developed to prevent organ rejection in adult patients undergoing kidney transplantation.

Creative Biolabs has been a long-term expert in the field of drug development. As a pioneer and the undisrupted global leader in half-life extension, we offer a variety of solutions to improve your productivity and streamline your research processes. If you are interested in our products or services, please do not hesitate to contact us for more detailed information.